scholarly journals Tumor markers and rectal cancer: Support for an inflammation-related pathway

2009 ◽  
Vol 125 (7) ◽  
pp. 1698-1704 ◽  
Author(s):  
Martha L. Slattery ◽  
Roger K. Wolff ◽  
Jennifer Herrick ◽  
Bette J. Caan ◽  
Wade Samowitz
Keyword(s):  
Rectal Cancer ◽  
Tumor Markers ◽  
Cancer Support ◽  
Related Pathway

scholarly journals Evaluation of potential tumor markers that may predict neoadjuvant treatment efficiency in rectal cancer

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Fatma Demet Arslan ◽  
Ayse Kocak ◽  
Cengiz Aydın ◽  
Emel Ebru Pala ◽  
Dilek Oncel ◽  
...  
Keyword(s):  
Gene Expression ◽  
Rectal Cancer ◽  
Tumor Markers ◽  
Locally Advanced ◽  
Neoadjuvant Treatment ◽  
Beclin 1 ◽  
Tumor Regression Grade ◽  
Protein Levels ◽  
Study Gene Expression ◽  
Regression Grade

AbstractObjectivesThe recurrence of rectal cancer or its resistance to neoadjuvant treatment develops due to the adaptation to hypoxia, apoptosis or autophagy. Survivin, one of the inhibitors of apoptosis; Beclin 1, which is a positive regulator in the autophagy pathway; and hypoxia-inducible factor-1α (HIF-1α) and carbonic anhydrase-9 (CA9), which are associated with tumor tissue hypoxia, may be related to resistance to treatment. Our aim was to evaluate the potential tumor markers that may help to monitor the response to neoadjuvant treatment in locally advanced rectal cancer (RC).MethodsTwenty-five patients with locally advanced RC were included in the study. Gene expression and protein levels of Beclin 1, Survivin, HIF-1α, and CA9 were analyzed in fresh tissue specimens and blood samples. The relationships of these markers to tumor staging and regression grade were evaluated.ResultsHigher blood CA9 gene expression levels and lower blood HIF-1α protein levels were found in the response group according to tumor regression grade. After neoadjuvant treatment, tissue Beclin 1 and blood Survivin gene expressions and tissue CA9, blood Beclin 1 and blood HIF-1α protein levels decreased significantly.ConclusionBeclin 1, Survivin, HIF-1α ve CA9 may help to predict the effects of the applied treatment approach.

scholarly journals Tumor Markers of Neo-Adjuvant Chemo-Radiation Response in Rectal Cancer

10.5772/28095 ◽  
2011 ◽  
Author(s):  
Jacintha N. ◽  
Mary Clare ◽  
John V.
Keyword(s):  
Rectal Cancer ◽  
Tumor Markers ◽  
Radiation Response

OC-0255: A prospective trial of short course radiation followed by FOLFOX chemotherapy for rectal cancer: Support for RAPIDO

2014 ◽  
Vol 111 ◽  
pp. S98
Author(s):  
P. Parikh ◽  
J. Olsen ◽  
B. Tan ◽  
S. Hunt ◽  
R. Myerson
Keyword(s):  
Rectal Cancer ◽  
Prospective Trial ◽  
Cancer Support ◽  
Short Course ◽  
Folfox Chemotherapy

Intravoxel Incoherent Motion MRI of Rectal Cancer: Correlation of Diffusion and Perfusion Characteristics With Prognostic Tumor Markers

2018 ◽  
Vol 210 (4) ◽  
pp. W139-W147 ◽  
Author(s):  
Hongliang Sun ◽  
Yanyan Xu ◽  
Aiping Song ◽  
Kaining Shi ◽  
Wu Wang
Keyword(s):  
Rectal Cancer ◽  
Tumor Markers ◽  
Intravoxel Incoherent Motion ◽  
Motion Mri

Differences in serum tumor markers between colon and rectal cancer

1996 ◽  
Vol 39 (7) ◽  
pp. 799-805 ◽  
Author(s):  
Monika A. Carpelan-Holmström ◽  
Caj H. Haglund ◽  
Peter J. Roberts
Keyword(s):  
Rectal Cancer ◽  
Tumor Markers ◽  
Serum Tumor Markers ◽  
Colon And Rectal Cancer

Cancer support nurses: a co-ordinating role in cancer care

1998 ◽  
Vol 7 (2) ◽  
pp. 125-128 ◽  
Author(s):  
McILLMURRAY ◽  
CUMMINGS ◽  
HOPKINS ◽  
McCANN
Keyword(s):  
Cancer Care ◽  
Cancer Support

Use of Tumor Markers in Lung Cancer

1994 ◽  
Vol 8 (3) ◽  
pp. 507-532 ◽  
Author(s):  
Gary M. Strauss ◽  
Arthur T. Skarin
Keyword(s):  
Lung Cancer ◽  
Tumor Markers

Abstract #832 Tumor Markers in Functional and Silent Corticotroph Adenomas

2018 ◽  
Vol 24 ◽  
pp. 189-190
Author(s):  
Adriana Gonzalez ◽  
Daniel Brat ◽  
Emir Veledar ◽  
Nelson Oyesiku ◽  
Daniel Barrow ◽  
...  
Keyword(s):  
Tumor Markers ◽  
Corticotroph Adenomas

Surgery, Radio- and Chemo- therapy for Multimodal Treatment of Rectal Cancer

Swiss Surgery ◽  
2001 ◽  
Vol 7 (6) ◽  
pp. 256-274 ◽  
Author(s):  
Link ◽  
Staib ◽  
Kornmann ◽  
Formentini ◽  
Schatz ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Multimodal Treatment ◽  
Local Relapse ◽  
Phase Iii ◽  
Neoadjuvant Radiotherapy ◽  
Term Survival ◽  
Primary Tumors ◽  
Impact On Survival ◽  
Relapse Rates

The possibilities and results of multimodal treatment in rectal cancer were reviewed with respect to the results of surgical treatment only. Based on the results of 4 studies, reducing local relapse rates and increasing long term survival rates significantly, postoperative radiochemotherapy (RCT) + chemotherapy (CT) should remain the recommended standard for R0 resected UICC II and III rectal cancers. The addition of RT to adjuvant CT reduces local relapses without significant impact on survival (NSABP R-02). Vice versa, the addition of CT to RT or an improved CT in the RCT-concept prolongs survival. Preoperative neoadjuvant radiotherapy (RT) reduced local relapse rates in 9 studies, and extended survival in one study that evaluated all eligible patients. Preoperative RT reduced local relapse rates in addition to total mesorectal excision (TME) but did not extend survival. The preoperative RCT + CT downstages resectable and nonresectable tumors and induces a higher sphincter preservation rate. Phase III data justifying its routine use in all UICC II + III stages are not yet available. This treatment may be routinely applied in nonresectable primary tumors or local relapses. Preoperative RCT (or RT) may evolve as standard, if the patient selection is improved and postoperative morbidity and long term toxicity reduced. Intraoperative RT could be added to this concept or be used together with preoperative/postoperative RT at the same indications. Postoperative adjuvant RT reduced local relapses significantly in a single trial, and no impact on survival time is reported. Since postoperative RT is inferior to preoperative RT, this treatment cannot be recommended, if RT is chosen as a single treatment modality in adjunction to surgery. The results of local tumor excisions may be improved with pre- or postoperative RCT + CT. In the future, multimodal treatment of rectal cancer might be more effective, if individualized according to prognostic factors.

Sign in / Sign up

Export Citation Format

Share Document